# RDEA119 and Sorafenib Combination Dose Escalation Study

> **NCT00785226** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 62 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** RDEA119
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00785226
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785226, "RDEA119 and Sorafenib Combination Dose Escalation Study". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00785226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*